Natasha Hernday - 11 Jun 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director
Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
11 Jun 2025
Net transactions value
$0
Form type
4
Filing time
13 Jun 2025, 19:30:15 UTC
Previous filing
23 May 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Natasha Hernday filed Form 4 for Janux Therapeutics, Inc. (JANX) on 13 Jun 2025."

Quick Takeaways

  • This page summarizes Natasha Hernday's Form 4 filing for Janux Therapeutics, Inc. (JANX).
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 13 Jun 2025, 19:30.

What Changed

  • Previous filing in this sequence was filed on 23 May 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hernday Natasha Director C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO /s/ James Pennington, Attorney-in-Fact 13 Jun 2025 0001780547

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Award $0 +3,750 +75% $0.000000 8,731 11 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +11,667 $0.000000 11,667 11 Jun 2025 Common Stock 11,667 $25.46 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
F2 The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

Sponsored